BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 17606669)

  • 21. Duloxetine in major depressed patients resistant to SSRIs and/or venlafaxine.
    Pitchot W; Scantamburlo G; Ansseau M
    Psychiatr Danub; 2010 Nov; 22 Suppl 1():S106-7. PubMed ID: 21057413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Duloxetine treatment of social anxiety disorder with comorbid major depression.
    Lin CC
    J Clin Psychopharmacol; 2008 Oct; 28(5):591-2; author reply 592-3. PubMed ID: 18794669
    [No Abstract]   [Full Text] [Related]  

  • 23. Bleeding gums: duloxetine may be the cause.
    Balhara Y; Sagar R; Varghese ST
    J Postgrad Med; 2007; 53(1):44-5. PubMed ID: 17244971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels.
    Volonteri LS; Colasanti A; Cerveri G; Fiorentini A; De Gaspari IF; Mauri MC; Valli A; Papa P; Mencacci C
    J Psychopharmacol; 2010 Aug; 24(8):1193-9. PubMed ID: 19406851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
    Lam RW; Lönn SL; Despiégel N
    Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Physical recovery is part of remission].
    Krankenpfl J; 2004; 42(3-4):110. PubMed ID: 15311907
    [No Abstract]   [Full Text] [Related]  

  • 27. Hypogonadism and gynecomastia with duloxetine.
    Weydt P; Schönfeldt-Lecuona CJ; Gahr M; Connemann BJ
    Pharmacopsychiatry; 2011 Mar; 44(2):77. PubMed ID: 21298612
    [No Abstract]   [Full Text] [Related]  

  • 28. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications.
    Maund E; Tendal B; Hróbjartsson A; Jørgensen KJ; Lundh A; Schroll J; Gøtzsche PC
    BMJ; 2014 Jun; 348():g3510. PubMed ID: 24899650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonin-norepinephrine reuptake inhibitor treatment for tinnitus and depression.
    Chang JP; Wu CC
    J Clin Psychopharmacol; 2012 Oct; 32(5):729. PubMed ID: 22926618
    [No Abstract]   [Full Text] [Related]  

  • 30. Duloxetine--three birds with one stone?
    Michel MC
    Int J Clin Pract; 2007 Aug; 61(8):1247-8. PubMed ID: 17627705
    [No Abstract]   [Full Text] [Related]  

  • 31. A case of apical ballooning cardiomyopathy associated with duloxetine.
    Bergman BR; Reynolds HR; Skolnick AH; Castillo D
    Ann Intern Med; 2008 Aug; 149(3):218-9. PubMed ID: 18678857
    [No Abstract]   [Full Text] [Related]  

  • 32. Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study.
    Maund E; Tendal B; Hróbjartsson A; Lundh A; Gøtzsche PC
    BMJ; 2014 Jun; 348():g3555. PubMed ID: 24899651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
    Goldstein DJ; Mallinckrodt C; Lu Y; Demitrack MA
    J Clin Psychiatry; 2002 Mar; 63(3):225-31. PubMed ID: 11926722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A case of hyponatremia induced by duloxetine.
    Safdieh JE; Rudominer R
    J Clin Psychopharmacol; 2006 Dec; 26(6):675-6. PubMed ID: 17110834
    [No Abstract]   [Full Text] [Related]  

  • 35. Duloxetine in the treatment of social anxiety disorder.
    Crippa JA; Filho AS; Freitas MC; Zuardi AW
    J Clin Psychopharmacol; 2007 Jun; 27(3):310. PubMed ID: 17502786
    [No Abstract]   [Full Text] [Related]  

  • 36. The use of Duloxetine in the treatment of male stress urinary incontinence.
    Fink KG; Huber J; Würnschimmel E; Schmeller NT
    Wien Med Wochenschr; 2008; 158(3-4):116-8. PubMed ID: 18330528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reboxetine: a norepinephrine selective reuptake pump inhibitor.
    Preskorn SH
    J Psychiatr Pract; 2004 Jan; 10(1):57-63. PubMed ID: 15334987
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine.
    Trivedi MH; Desaiah D; Ossanna MJ; Pritchett YL; Brannan SK; Detke MJ
    Int Clin Psychopharmacol; 2008 May; 23(3):161-9. PubMed ID: 18408530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study.
    Seguí J; López-Muñoz F; Alamo C; Camarasa X; García-García P; Pardo A
    J Psychopharmacol; 2010 Aug; 24(8):1201-7. PubMed ID: 19282423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is treatment-associated hypomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depression.
    Dunner DL; D'Souza DN; Kajdasz DK; Detke MJ; Russell JM
    J Affect Disord; 2005 Jul; 87(1):115-9. PubMed ID: 15967235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.